| Oct 31 |
Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024
|
| Sep 16 |
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
|
| Aug 29 |
Scinai Immunotherapeutics regains compliance with Nasdaq listing rule
|
| Aug 29 |
Scinai Regains Full Compliance with Nasdaq Listing Requirements
|
| Aug 21 |
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
|
| Aug 20 |
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript
|
| Aug 20 |
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
|
| Aug 16 |
Scinai Immunotherapeutics reports H1 results
|
| Aug 15 |
Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23
|
| Jul 23 |
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb
|
